Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.81 |
| ▸ | HTT | P42858 | 1/20 | 0.81 |
| ▸ | CA1 | P00915 | 3/20 | 0.78 |
| ▸ | CA2 | P00918 | 3/20 | 0.78 |
| ▸ | CA12 | O43570 | 2/20 | 0.78 |
| ▸ | CA3 | P07451 | 2/20 | 0.78 |
| ▸ | CA4 | P22748 | 2/20 | 0.78 |
| ▸ | CA6 | P23280 | 2/20 | 0.78 |
| ▸ | CA5A | P35218 | 2/20 | 0.78 |
| ▸ | CA7 | P43166 | 2/20 | 0.78 |
| ▸ | CA9 | Q16790 | 2/20 | 0.78 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.78 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.78 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.78 |
| ▸ | PGR | P06401 | 2/20 | 0.59 |
| ▸ | MMP1 | P03956 | 4/20 | 0.55 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | MMP2 | P08253 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17907417 | 0.90 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAHTTCA1CA2 | |
| SCHEMBL2442745 | 0.88 | CA1 (1.00) | SMN1; SMN2LMNAHTTCA1CA2 | |
| SCHEMBL11512091 | 0.86 | CA1 (0.95) | SMN1; SMN2LMNAHTTCA1CA2 | |
| SCHEMBL10617367 | 0.86 | CA1 (0.95) | SMN1; SMN2LMNAHTTCA1CA2 | |
| SCHEMBL618590 | 0.83 | LMNA (0.85) | SMN1; SMN2LMNAHTTPGRMMP1 | |
| SCHEMBL8736878 | 0.83 | SMN1; SMN2 (0.85) | SMN1; SMN2LMNAHTTCA1CA2 | |
| SCHEMBL28750635 | 0.81 | SMN1; SMN2 (0.81) | SMN1; SMN2LMNAHTTCA1CA2 | |
| SCHEMBL11245748 | 0.81 | SMN1; SMN2 (0.81) | SMN1; SMN2LMNAHTTCA1CA2 | |
| SCHEMBL24631132 | 0.80 | CA12 (0.54) | SMN1; SMN2LMNAHTTCA1CA2 | |
| SCHEMBL7008902 | 0.80 | SMN1; SMN2 (0.79) | SMN1; SMN2LMNAHTTCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1021413-B1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | WYETH CORP (US) | 2003-06-11 | — | — | EP | disclosed |
| US-6548524-B2 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors | AMERICAN CYANAMID COMPANY | 2003-04-15 | — | — | US | disclosed |
| US-6534491-B2 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors | AMERICAN CYANAMID COMPANY | 2003-03-18 | — | — | US | disclosed |
| US-6498167-B2 | NITROGEN CONTAINING BICYCLIC HETEROAROMATIC COMPOUND CONTAINING SULFONAMIDE AND HYDROXYAMIDE GROUPS, USEFUL IN TREATMENT OF ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, BONE DISEASE AND HIV INFECTIONS | AMERICAN CYANAMID COMPANY | 2002-12-24 | — | — | US | disclosed |
| US-20020132826-A1 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors | WYETH HOLDINGS CORPORATION | 2002-09-19 | — | — | US | disclosed |
| US-20010046989-A1 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors | WYETH HOLDINGS CORPORATION | 2001-11-29 | — | — | US | disclosed |
| US-20010025047-A1 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors | WYETH HOLDINGS CORPORATION | 2001-09-27 | — | — | US | disclosed |
| US-6228869-B1 | ANTITUMOR, ANTIMETASTASIS, ANTIARTHRITIC, AND WOUND HEALING AGENTS; QUINOLINE AND ISOQUINOLINE DERIVATIVES | AMERICAN CYANAMID COMPANY | 2001-05-08 | — | — | US | disclosed |
| EP-1021413-A1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | American Cyanamid Company (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-1999018076-A1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132826-A1 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors | MSR1, TIMP3, OGFR | SMN1; SMN2 3389/4885LMNA 1901/4885HTT 4285/4885 |
| US-20010025047-A1 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors | MSR1, TIMP3, TGFBR2 | SMN1; SMN2 3228/4885LMNA 1684/4885HTT 4356/4885 |
| US-20010046989-A1 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors | MSR1, TIMP3, TGFBR2 | SMN1; SMN2 3126/4885LMNA 1809/4885HTT 4295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.